Establishment of The Effective and Safe Anticoagulation Therapy for Japanese Patients
Establishment of The Effective and Safe Anticoagulation Therapy for Japanese Patients
批准号:
12670703
负责人:
TAKAHASHI Harumi
金额:
$2.05万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001
中文摘要
点击翻译按钮获取中文摘要
英文摘要
To investigate the population differences in the metabolic activity of cytochrome P450 (CYP) 2C9 between genotypically-matched Caucasians and Japanese using the unbound oral clearance (CLpo,u) of (S)-warfarin as an in vivo probe.Ninety Japanese and 47 Caucasian patients on maintenance warfarin therapy were studied. Steady-state plasma unbound concentrations (Cu) of (S)-warfarin were measured by a chiral HPLC method coupled with ultrafiltration techniques. CLpo,u for (S)-warfarin and the formation clearance (CLm) of (S)-7-hydroxywarfarin were determined. Genotyping of CYP2C9 was performed with a polymerase chain reaction method for 6 distinct alleles (CYP2C9^*1, CYP2C9^*2, CYP2C9^*3, CYP2C9^*4, CYP2C9^*5 and a T/C transition in intron 2).The frequency distribution of CLpo,u for (S)-warfarin obtained from Japanese was shifted towards higher values as compared to that in Caucasians. Japanese had lower allelic frequencies for the 5 variants than Caucasians. When inter-population comparison … More s of CYP2C9 activity were made for genotype-matched subjects, Japanese with the homozygous CYP2C9^*1 (wild-type) genotype (n = 85) had significantly (p<0.01) greater median values for CLpo,u and CLm than the Caucasians with the corresponding genotype (n = 26) : 10.4 vs 4.25 ml/min/kg and 0.015 vs 0.010 ml/min/kg, respectively. In addition, heterozygous Japanese for the CYP2C9^*3 genotype (n = 4) showed a significantly (p<0.05) reduced CLpo,u for (S)-warfarin by 63 % as compared with Japanese possessing the homozygous CYP2C9^*1 genotype. By contrast, no significant differences were observed in this parameter among the Caucasian with the homozygous CYP2C9^*1 genotype and those with heterozygous CYP2C9^*2 or CYP2C9^*3 genotypes.These findings indicate that inter-population differences in the frequencies of known variant CYP2C9 alleles account only in part for the variability observed in in vivo CYP2C9 activity in different populations. Additionally, a gene-dose effect of defective CYP2C9 alleles on the in vivo CYP2C9 activity is evident in Japanese but not in Caucasians. Further studies are required to identify concealed factor(s) (e.g., transcriptional regulation) responsible for the large intra- and inter-population variability in CYP2C9 activity. Less
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Harumi Takahashi: "Developmental changes in pharmacokinetics and pharmacodynamics of Warfarin enantiomers in Japanese children"Clinical Pharmacology and Therapeutics. 68. 541-555 (2000)
Harumi Takahashi:“日本儿童华法林对映体药代动力学和药效学的发展变化”临床药理学和治疗学。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Harumi Takahashi: "Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin"Pharmacogenetics. 8. 365-373 (1998)
Harumi Takahashi:“(S)-华法林体外和体内代谢的比较”药物遗传学。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Harumi Takahashi: "Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children"Clinical Pharmacology and Therapeutics. 68・5. 541-555 (2000)
Harumi Takahashi:“日本儿童华法林对映体的药代动力学和药效学的发展变化”临床药理学和治疗学 68・5(2000)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
高橋晴美: "肝代謝型薬剤のPK/PD情報に基づく小児薬用量の設定"日本小児臨床薬理雑誌. (印刷中).
Harumi Takahashi:“根据肝脏代谢药物的 PK/PD 信息设置儿科剂量”,《日本儿科临床药理学杂志》(出版中)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Harumi Takahashi: "Pharmacogenetics of warfarin elimination and its clinical implications"Clinical Pharmacokinetics. 40. 587-603 (2001)
Harumi Takahashi:“华法林消除的药物遗传学及其临床意义”临床药代动力学。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 9 条
The role of Epac2A/Rap1 signaling in the protection of pancreatic beta-cell
-
批准号:16K09749
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.0万
-
财政年份:2016
-
负责人:TAKAHASHI Harumi
-
依托单位:
Establishment of pharmacogenetic-based dosing algorithm of warfarin for Asian, Caucasian and African American patients
-
批准号:23590652
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.33万
-
财政年份:2011
-
负责人:TAKAHASHI Harumi
-
依托单位:
The Role of Epac2 as a new target of sulfonylurea drugs
-
批准号:22790860
-
项目类别:Grant-in-Aid for Young Scientists (B)
-
资助金额:$2.58万
-
财政年份:2010
-
负责人:TAKAHASHI Harumi
-
依托单位:
Individualization of anticoagulation therapy of warfarin based on pharmacogenetic information
-
批准号:20590548
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.0万
-
财政年份:2008
-
负责人:TAKAHASHI Harumi
-
依托单位:
Studies on production of resistant variant of Japanese pear 'Osa Nijisseiki' to Alternaria alternata Japanese pear pathotype by means of somatic mutation.
-
批准号:13660039
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.11万
-
财政年份:2001
-
负责人:TAKAHASHI Harumi
-
依托单位: